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Abstract
Background: The C-terminal region of merozoite surface protein-1 (MSP-1) is one of the leading
candidates for vaccination against the erythrocytic stages of malaria. However, a major concern in
the development of MSP-1 based malaria vaccine is the polymorphism observed in different
geographical Plasmodium falciparum isolates. To explore whether the sequence heterogeneity of
PfMSP-1 leads to variation in naturally acquired anti-MSP-119 antibodies, the present study was
undertaken to study PfMSP-119 sequence polymorphism in malaria-endemic villages in eastern India
and also carried out a competition enzyme-linked immunosorbent assay using three PfMSP-119
variant forms.
Methods: The sequence variations in the C-terminal region of PfMSP-119 were determined in a
malaria endemic region. Three PfMSP-119  variants were produced in Escherichia coli
(PfMSP119QKNG-L, PfMSP119EKNG-L and PfMSP119ETSR-F) and an immunodepletion assay was
carried out using the corresponding patients' sera.
Results: Results revealed predominance of PfMAD20 allele among Indian field isolates. Seven
PfMSP-119 variant forms were isolated in a singe geographical location. Three of PfMSP-119 variant
forms when expressed in E. coli showed presence of cross-reaction as well as variant specific
antibodies in malaria infected patient sera.
Conclusion: The present study demonstrates the existence of allele specific antibodies in P.
falciparum-infected patient sera, however their role in protection requires further investigation.
These results thereby, suggest the importance of a multi-allelic PfMSP-119 based vaccine for an
effective malaria control.
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Background
Malaria is one of the major causes of death from infection
in developing countries. Development of an effective
malaria vaccine may reduce malaria-associated severe
morbidity and mortality in malaria-endemic areas. A
number of parasite surface antigens of asexual blood
stages are being investigated as vaccine candidate anti-
gens. [1,2]. Among these antigens, merozoite surface pro-
tein-1 (MSP-1) is a leading candidate antigen [3]. The msp-
gene encodes a 195 kDa protein that is cleaved in four dis-
tinct fragments (83, 28–30, 38–45 and 42 kDa) at the
time of schizont rupture. During merozoite invasion, the
carboxy-terminal 42-kDa fragment is further processed to
yield a 19-kDa fragment (MSP-119) which remains associ-
ated with merozoites [4,5]. A number of vaccination stud-
ies with MSP-119 and MSP-142, in mice and monkeys have
shown partial and full protection from malaria infection
[6-11]. A substantial proportion of antibodies directed to
MSP-119 in  Plasmodium falciparum-infected human sera
have been shown to inhibit erythrocyte invasion in vitro
[12]. Importantly, MSP-119-mediated protective immune
responses are largely antibody dependent with high anti-
body titres being essential for the protection [13,14].
The msp-1 of P. falciparum has been shown to be dimor-
phic, K1/Wellcome and MAD 20 types [15,16]. Sequence
comparison of P. falciparum msp-1 sequences among dif-
ferent geographical isolates shows a great deal of varia-
tions. Based on sequence analysis, msp-1 has been divided
into 17 blocks comprising of conserved, semi conserved
and variable regions [5,15]. Intragenic recombination
between the two allelic types appears to be the main cause
for variability among different field isolates [16-18]. The
C-terminal 19 kDa region of msp-1, that represents the
17th block, consists of two EGF like domains [5] and has
been shown to be highly conserved among different iso-
lates, with single amino acid substitution at five different
positions. These changes are E µ Q at position 1644 in the
first EGF domain and at positions, 1691 (T µ K), 1700 (S
µ N), 1701 (R µ G) and 1716 (L µ F) [19]. Based on these
variations, several variant forms of PfMSP-119 have been
described among different P. falciparum isolates around
the world. However, there are a limited number of reports
of genetic diversity of C-terminal region of MSP-119 in iso-
lates from the Indian subcontinent [18,20,21], that con-
tribute around two million cases every year (Source:
National Vector Borne Disease Control Programme).
The present study investigated sequence variations in
MSP-119  region among different field isolates from a
malaria endemic area in India. This study reveals existence
of seven variant types in a single geographical location. In
addition, three of the MSP-119 variants, Q-KNG-L, E-KNG-
L and E-TSR-F were expressed and the relative abundance
of specific antibodies in their respective sera studied.
Methods
Collection of P. falciparum infected blood and sera
P. falciparum infected blood samples were collected on fil-
ter paper by finger prick from malaria patients participat-
ing in cross-sectional and longitudinal malaria
epidemiology surveys being conducted in malaria
endemic villages in Sundergarh district, Orissa in eastern
India [23]. Thirteen study villages were chosen, out of
which eight villages were located in deep forests and five
villages were located in plain areas. Prior consent of the
patients and the consent of institutional ethical commit-
tee were taken before the beginning of the study. Age of
the patients ranged between six months to 17 years. In
case of infants, the consent of parents were obtained. All
the samples were positive for P. falciparum infection as
determined by Giemsa-stained thick smears examined
microscopically. Sixteen field spots were chosen from six
different villages and DNA was isolated from these spots
by the boiling method [24]. Blood samples were also col-
lected and allowed to clot at room temperature, and
serum was collected by centrifugation at 2,000 rpm for 10
min at 4°C and stored at -20°C until used.
PCR amplification, cloning and sequencing
To determine the sequence polymorphism in PfMSP-119
gene, PCR amplification was done in a 50 µl reaction vol-
ume using 10 ng genomic DNA from different P. falci-
parum isolates and primers MSP1-19F1 (Forward: 5' ATT
GAG ACC TTA TAC AAT AAC 3') and MSP1-19R1
(Reverse: 5' TTA AGG TAA CAT ATT TTA ACT CCT AC 3').
The thermocycler profile was 5 min hot start at 94°C and
30 cycles each of 30 sec at 94°C, 1 min at 50°C and 30 sec
at 72°C. In some cases, nested PCR was employed using a
second set of forward primer MSP1-19F2 (Forward: 5'
GAT ACG AAA AAA GAT ATG CTT GG 3') and the same
reverse primer. The amplified PCR products (480 bps)
were analysed by agarose gel electrophoresis and purified
by QIAquick Gel Extraction Kit (Qiagen). The purified
PCR fragments were cloned into pGEM-T cloning vector
as per manufacturer's instructions (Promega). The posi-
tive clones were selected by restriction enzyme analysis.
Three independent clones from a minimum of two PCR
amplifications for each isolate were sequenced using T7
forward and M13 reverse primers.
Expression and purification of three PfMSP-119 variants
For the expression of PfMSP-119 variants, the 288-bp frag-
ment corresponding to PfMSP-119 region were amplified
using primers; 5'-GACTAGGGATCCATTTCACAACAC-
CAATGCG-3' and 5'-GCTGATGTCGACTTAGTTAGAG-
GAACTGCAGAA-3' and cloned into pQE-30 expression
vector in BamHI and SalI sites. This vector provides six His
residues at the N terminus of the expressed protein.
Expression of the recombinant MSP-119 was induced with
0.5 mM IPTG in the Escherichia coli strain M15. For theMalaria Journal 2007, 6:95 http://www.malariajournal.com/content/6/1/95
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purification of MSP-119 proteins, the induced pellets were
sonicated in 1 × TBS (Tris 50 mM, NaCl 500 mM), pH 8.0
containing 1 mM PMSF and 0.05% Tween 20. The super-
natant containing the expressed proteins were incubated
with Nickel-NTA-Agarose for 1 h at room temperature.
The resins were washed with 1 × TBS containing 10 mM
imidazole. The bound proteins were eluted with an imi-
dazole gradient of 20 to 250 mM at pH 8.0. Q-KNG-L var-
iant was eluted with a linear gradient of 10 to 70 mM
Imidazole in 20 mM Tris-500 mM NaCl (pH 8.0) buffer,
E-KNG-L variant was eluted in a linear gradient of 50–250
mM and E-TSR-F was eluted in 250 mM Imidazole. The
eluates were analysed by SDS-PAGE, the fractions contain-
ing a clear single protein band were pooled, and the pro-
tein concentrations were determined.
ELISA
Reactivity of the recombinant PfMSP-119 proteins with
patient sera was evaluated by ELISA as described earlier
[25]. Briefly, 96-well microplates (Dynatech) were coated
with 50 ng of any of the three recombinant PfMSP-119
proteins per well in 0.06 M carbonate-bicarbonate buffer
(pH 9.6). The plates were incubated overnight at 4°C, and
the wells were blocked with 5% low-fat milk in PBS (pH
7.2) for 1 h at room temperature. The antigen-coated wells
were sequentially incubated with serial dilutions (starting
from 1:50 dilutions) of the individual patient sera and
optimally diluted enzyme-labelled secondary antibody
(horseradish peroxidase-labeled antihuman immu-
noglobulin, IgG). In between these incubations, the plates
were washed with a 0.05% solution of Tween 20 in PBS.
The enzyme reaction was developed with o-phenyledi-
amine dihydrochloride-H2O2 in citrate phosphate buffer
(pH 5.0), stopped with 8 N H2SO4, and recorded at 490
nm by use of a microplate reader (Molecular Devices).
Antibody depletion assay
To determine the relative abundances of antibodies spe-
cific for a PfMSP119  variant in P. falciparum-infected
human sera, an antibody depletion assay was carried out
as described earlier [25]. The wells of flat-bottom Immu-
nolon-2 plates were coated with 100 ng of each of the
PfMSP-119  recombinant antigens, namely
PfMSP119QKNG-L, PfMSP119EKNG-L and
PfMSP119ETSR-F. The wells were blocked with 5% low-fat
milk in PBS (pH 7.2) for 1 h at room temperature. After
blocking, all of the wells were washed with 0.05% Tween
20 in PBS and then with PBS (pH 7.2), the first two wells
in the first column were incubated for ten minutes with P.
falciparum-infected human sera of the respective sequence
variants at a dilution of 1:100, while the remaining wells
contained only wash buffer. The sera from the first two
wells were transferred to the next respective wells in the
second column and incubated for half an hour. These
serial incubations were carried out until all of the antibod-
ies with respect to a particular antigen were depleted, as
determined by color development in the wells by a stand-
ard ELISA. It was observed that for all the sequence vari-
antss, antigen-specific antibodies were completely
removed from the respective sera after six serial transfers
except in the case of Q-KNG-L variant which depleted the
sera after nine serial transfers. All these antibody-depleted
sera were subsequently analysed for their cross reactivity
with each of the PfMSP119 variants; PfMSP119Q-KNG-L, E-
KNG-L and PfMSP119E-TSR-F antigens by ELISA. The reac-
tivity of each protein with the other two depleted sera was
compared with the undepleted sera to analyse the relative
contribution of each antigen.
Results
Epidemiology of malaria transmission in malaria endemic 
villages in Orrisa, India
Thirteen study villages were chosen, out of which eight vil-
lages were located in deep forests and five villages were
located in plain areas. A detailed study of the epidemiol-
ogy of malaria transmission was done in these villages
from January 2001 to December 2003 and was reported
[26]. Briefly, malaria transmission is perennial but is
markedly low in the plain area than forest area. Plasmo-
dium falciparum accounted for 85% of total malaria cases
during the study period. In forest and plain areas, the
number of P. falciparum cases per thousand populations
were 284.1 and 31.2 respectively, whereas the parasite rate
was 14% and 1.7% respectively. In forest areas, clinical
malaria occurred more frequently in children aged 0–5
years and declined gradually with increasing age. Anophe-
les fluvialitis and Anopheles culicifacies were the two vector
species responsible for malaria transmission in these vil-
lages. The entomological inoculation rate in the forest and
plain areas was 0.311 and 0.014 infective bites/person/
night, respectively during 2003. The peak of malaria inci-
dence coincided with peak vector density of A. fluvialitis,
suggesting that this is the predominant vector for malaria
transmission in these villages. Parasite density with a geo
mean density of more than 2000 were detected in 211
patients in the forest area as compared to 28 patients in
the plain area.
Sequence polymorphism in PfMSP-119 gene
To determine the extent of polymorphism of MSP-119 in a
natural population of P. falciparum in India, the C-termi-
nal region of MSP-119 gene corresponding to 16th block (a
variable region) and 17th block (a conserved region) was
amplified from 16 P. falciparum isolates. The amplified
fragments were sequenced and these sequences were com-
pared with that of two prototypic alleles, MAD20 and K1/
Wellcome (Figure 1). Comparison of the sequences
between 1594 and 1630 aa that correspond to the 3' end
of 16th block, showed that all these field isolates belong to
one of the two prototypic alleles, MAD20. Existence ofMalaria Journal 2007, 6:95 http://www.malariajournal.com/content/6/1/95
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both allelic forms in a single isolate was not observed. All
the sequences corresponding to 16th block were highly
conserved; only a few variations were seen in two of the 16
isolates. A change K µ R was observed at amino acid posi-
tion 1603 in one of the isolate, BM8-55. These results sug-
gested the predominance of MAD 20 allelic type among
these field isolates in India.
In block 17 which represents the C-terminal, cysteine-rich
19 kDa fragment of MSP-1 (1631–1744), the nucleotide
and the deduced amino acid sequences were found to be
highly conserved with only five substitutions seen at posi-
tions, 1644 (E µ Q), 1691 (T µ K), 1700 (S µ N), 1701 (G
µ R) and 1716 (L µ F) among Indian isolates (Fig. 1). All
the nucleotide changes in these isolates were non-synon-
ymous, as a result, the deduced amino acid variation cor-
responded to one or other allele. Based on these five
changes, seven different allelic forms were identified,
many of which have been reported earlier [19]. Among
the several alleles of PfMSP-119, Q-KNG-L allele was seen
in 5/16 isolates, while E-KNG-L and E-TSR-L alleles were
observed in 3/16 isolates. Existence of two allelic forms in
a single patient was not observed. Table 1 shows the dis-
tribution of different allelic types among theses Indian
isolates. In addition to the reported combinations of the
allele determining residues, we observed two novel allelic
forms, E-TSR-F and E-TNR-L that have been predicted ear-
lier [19]. Few other substitutions was seen in one of the
isolate BM8-32, at positions 1701 (K µ Q) and 1710 (K µ
N). Changes as reported in other geographical locations
[19,27] were not observed among these Indian isolates.
Expression of three PfMSP-119 variants and epitope 
sharing among these isolates
The sequenced PfMSP-119 gene fragment corresponding to
three variant types (Q-KNG-L, E-KNG-L and E-TSR-F) iso-
lated from P. falciparum infected patients (BK-62, PP3-18
and CM3-56) were cloned into pQE-30 vector and expres-
sion was induced with IPTG. All the three PfMSP-119 vari-
ants were expressed in soluble form and the proteins were
purified up to 85% by Ni-NTA2+ chromatography. The
three variant forms of PfMSP-119 migrated as a single
major band on SDS-PAGE under reducing conditions and
had apparent molecular mass of ~17–19 kDa (Figure 2A).
Escherichia coli-expressed PfMSP-119 variants were recog-
nized by monoclonal antibody, 12.10 and a polyclonal
Sequence diversity in the C-terminal region (blocks 16 and 17) of MSP-1 in Indian P. falciparum isolates in a single geographical  location Figure 1
Sequence diversity in the C-terminal region (blocks 16 and 17) of MSP-1 in Indian P. falciparum isolates in a single geographical 
location.Malaria Journal 2007, 6:95 http://www.malariajournal.com/content/6/1/95
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antibody raised against Q-KNG-L variant type (Figures 2B
and 2C). These results were in accordance with previous
findings [28].
To examine the cross-reactive epitopes in the three variant
types, an ELISA assay was carried out using their respective
sera and with sera obtained from patients showing other
variant types. As shown in Figure 3, the three variant types
showed reactivity with each sera; however the extent of
reactivity varied with the patient sera. To determine the
contribution of variant specific epitopes in the generation
of an immune response during a natural infection, an
immunodepletion assay was carried out. For the ELISA
depletion assay, sera from P. falciparum-infected patients
were absorbed with either of the variant recombinant pro-
teins in such a way that all of the antigen specific antibod-
ies were lost. The reactivity of the sera depleted was further
analysed with all the expressed PfMSP-119 variant forms.
As shown in Figure 4, when the sera from patient, BK3-62
expressing Q-KNG-L variant type was depleted with either
Q-KNG-L or E-KNG-L or E-TSR-F proteins, there was <
90% reduction in reactivity of the depleted sera with Q-
KNG-L antigen in comparison to its reactivity with unde-
pleted sera. These depleted sera also showed a reduction
of ~40–50% in its reactivity to other two PfMSP-119 vari-
ant types. Likewise, when sera from patients, PP3-18
expressing E-KNG-L variant type and CM3-56 expressing
E-TSR-F was depleted with either of the three PfMSP-119
variant forms, similar reduction was seen. These results
showed that PfMSP-119 variant specific immune responses
are generated in P. falciparum infected patients.
Discussion
Sequence heterogeneity in PfMSP-119 protein, a leading
vaccine candidate antigen for vaccination against erythro-
cytic stages of P. falciparum, may compromise its use as a
vaccine candidate antigen. Based on sequence variations
among different laboratory and field isolates, two proto-
typic alleles of P. falciparum MSP-1 represented by
PfMAD20 and PfK1/Wellcome have been described in
isolates from Africa, Asia and Latin America
[15,16,24,25]. The C-terminal 19 kDa region of MSP-1
(PfMSP-119) is a highly conserved region showing amino-
acid alterations at only five positions out of 102 residues.
Based on these alterations, about ten different PfMSP-119
allelic forms have been predicted in different field isolates
across the world [19].
Here, sequence diversity in MSP-119 region, among Indian
P. falciparum field isolates in malaria endemic villages in
same geographical location was investigated. Some of
these isolates have been previously analysed for sequence
variations in the receptor binding domain of PfEBA-175
[29]. Sequence data of the 16th block of MSP-1 revealed
that all the isolates were of PfMAD20 type. The present
study's results and the data obtained from previous stud-
ies clearly demonstrate that MAD20 allelic form predom-
inates among Indian PfMSP-1 isolates from different
geographical locations [18,20,30]. In the 17th block, seven
allelic forms was observed. Of these PfMSP-119 alleles, two
alleles (E-TNR-L & E-TSR-F) have not been reported ear-
lier, however, Qari et al (1998) have earlier predicted E-
TNR-L. These allelic forms seem to have generated due to
intragenic recombination between the two prototypic
Expression and immunoblot analysis of E. coli expressed  PfMSP-119 variants Figure 2
Expression and immunoblot analysis of E. coli expressed 
PfMSP-119 variants. (a) Coomassie blue-stained 12% SDS-
polyacrylamide gel of purified PfMSP-119 variants. (b & c) 
Immunoblot analysis to show the reactivity of PfMSP-119 vari-
ants with monoclonal antibodies (12.10) and with anti-
PfMSP119 (Q-KNG-L) antibody.
Table 1: Distribution of PfMSP-119 allelic types identified in Indian 
P. falciparum isolates.
S.No ISOLATE TYPE SEQUENCE
1. BK3-17 MAD20 E-TSR-L
2. BK3-62 WELLCOME Q-KNG-L
3. BM3-94 THAI Q-KNG-F
4. BM8-19 WELLCOME Q-KNG-L
5. BM8-32 MAD20 E-TSR-L
6. BM8-37 NOVEL E-TNR-L
7. BM8-4 WELLCOME Q-KNG-L
8. BM8-55 UGANDA E-KNG-L
9. BM8-70 MAD20 E-TSR-L
10. CM3-56 NOVEL E-TSR-F
11. DK3-16 UGANDA E-KNG-F
12. PP3-12 WELLCOME Q-KNG-L
13. PP3-18 UGANDA E-KNG-L
14. RM3-21 UGANDA E-KNG-L
15. RM3-51 WELLCOME Q-KNG-L
16. RM8-78 UGANDA E-KNG-LMalaria Journal 2007, 6:95 http://www.malariajournal.com/content/6/1/95
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alleles as suggested earlier because all the substituted
amino acids belonged to either one or other allelic form.
To know whether these five amino acid substitutions in
the PfMSP-119 region generate variant specific immune
responses in P. falciparum infected patients, three PfMSP-
119  variants (Q-KNG-L, E-KNG-L & E-TSR-F) were
expressed in an E. coli expression system with an N-termi-
nal His tag. Proteins were purified on a Ni2+-NTA column.
All the three PfMSP-119 recombinant forms were recog-
nized well by an invasion inhibitory monoclonal anti-
body (12.10) and anti-PfMSP-119 (Q-KNG-L) polyclonal
antibody. An earlier study [28] showed that the yeast
secreted recombinant MSP-119 variants are recognized by
polyclonal antibody raised against baculoproduced MSP1
(E-KNG) variant and by mAB 5B1 that is known to inhibit
invasion. Recognition of all the PfMSP-119 variants by
mAB 5B1 and 12.10 suggest that some of these protective
epitopes are not variant specific. A preliminary investiga-
tion of protective type IgG1/IgG3 antibody response to Q-
KNG-L sequence variant was carried out and significant
IgG1/IgG3 responses were observed in the infected sera
(data not shown). The frequency of IgG1 responses in dif-
ferent sera was quite similar while a significant difference
was seen within IgG3 responses as previously shown [31].
To determine the presence of variant specific antibodies
during the natural infection, sera from BK3-62, CM3-56
and PP3-18 patients were immuno-depleted using each of
the three recombinant antigens and the depleted sera were
analysed for reactivity with three variant antigens. Results
demonstrated that sera from P. falciparum infected
patients do contain cross-reactive as well as PfMSP-119 var-
iant specific antibodies. At present, it is difficult to say up
to what extent these variant specific antibodies contribute
to protective immune responses. Another aspect that
requires probing is the contribution of historic infections
with parasite of different sequence types. However, data
from a number of challenge studies have also provided
evidences for the variant specific immune responses.
Immunization of mice with recombinant PyMSP-119 pro-
tected mice against homologous but not heterologous
sporozoite or blood stage challenges [32,33]. In some
cases where some level of protection to heterologous
malarial challenge was seen, it was significantly lower
than the homologous challenge [6,34].
Conclusion
In summary, the present study has shown that PfMAD 20
is the major PfMSP-1 allelic form present in Indian popu-
lation and a number of PfMSP-119 allelic forms exist even
in a single geographical location in a malaria-endemic
region in India. The present study further show that signif-
icant levels of cross reactive antibodies are generated
against different PfMSP-119 allelic forms in a P. falciparum
infected natural human population. However, presence of
PfMSP-119 allele specific antibodies was also observed in
this population thus suggesting, for a better protection
against all strains of P. falciparum, it will be appropriate to
use a vaccine containing all possible sequence variants.
Although only three PfMSP-119 variants were expressed
and subsequently analysed for the presence of specific
antibodies in the present study, a detailed study is
required to clearly understand the role of PfMSP-119 vari-
ants in eliciting a protective immune response.
Immunodepletion assay showing the presence of PfMSP119  allele specific antibodies in sera from P. falciparum infected  patients Figure 4
Immunodepletion assay showing the presence of PfMSP119 
allele specific antibodies in sera from P. falciparum infected 
patients. Error bars indicate S.D.
Reactivity of PfMSP-119 variants in an ELISA with sera col- lected from P. falciparum infected patients at a dilution of  1:200 Figure 3
Reactivity of PfMSP-119 variants in an ELISA with sera col-
lected from P. falciparum infected patients at a dilution of 
1:200. Error bars indicate S.D.Malaria Journal 2007, 6:95 http://www.malariajournal.com/content/6/1/95
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